Sign in
4

Changes in Ownership

Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-22-015830

EVP & Chief Commercial Officer sold 2,713 shares at $66.62 ($180,740)

  • EVP & Chief Commercial Officer acquired 14,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Harris Erik EVP & Chief Commercial Officer 2022-03-01 Sale −2,713 $66.62 $180,740 22,317 D: show line 1 in the form
Harris Erik EVP & Chief Commercial Officer 2022-03-01 Grant or award +14,000 36,317 D: show line 2 in the form
Open-market sales · 2,713 sh · avg $66.62 · $180,740

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Harris Erik EVP & Chief Commercial Officer 2022-03-01 Grant or award · Stock Option (Right to Buy) +24,900 24,900 D: show line 3 in the form
Loading xslF345X03/doc4.xml…